You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
甘李藥業(603087.SH):美國子公司獲得FDA藥品臨牀試驗批准
格隆匯 08-05 16:54

格隆匯8月5日丨甘李藥業(603087.SH)公佈,公司全資子公司甘李藥業美國公司(Gan & Lee Pharmaceuticals USA Corporation)獲得美國食品藥品監督管理局(Food and Drug Administration,以下簡稱“FDA”)批准,同意門冬胰島素30注射液進行I期臨牀試驗(IND 143212)。

門冬胰島素30注射液是一款預混胰島素,由30%可溶性門冬胰島素和70%魚精蛋白門冬胰島素組成的雙時相混懸液。作為第三代胰島素類似物,其在改善血糖控制、減少低血糖風險、提高依從性以及節約醫療成本方面優勢明顯。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account